168 related articles for article (PubMed ID: 21373894)
1. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.
Rao VA; Zhang J; Klein SR; Espandiari P; Knapton A; Dickey JS; Herman E; Shacter EB
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1125-34. PubMed ID: 21373894
[TBL] [Abstract][Full Text] [Related]
2. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
Rao VA; Klein SR; Agama KK; Toyoda E; Adachi N; Pommier Y; Shacter EB
Cancer Res; 2009 Feb; 69(3):948-57. PubMed ID: 19176392
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
5. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
7. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
9. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.
Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA
Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975
[TBL] [Abstract][Full Text] [Related]
10. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
11. Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats.
Gonzalez Y; Pokrzywinski KL; Rosen ET; Mog S; Aryal B; Chehab LM; Vijay V; Moland CL; Desai VG; Dickey JS; Rao VA
Cancer Chemother Pharmacol; 2015 Sep; 76(3):447-59. PubMed ID: 26108538
[TBL] [Abstract][Full Text] [Related]
12. Iron chelator-induced up-regulation of Ndrg1 inhibits proliferation and EMT process by targeting Wnt/β-catenin pathway in colon cancer cells.
Chen Z; Sun J; Li T; Liu Y; Gao S; Zhi X; Zheng M
Biochem Biophys Res Commun; 2018 Nov; 506(1):114-121. PubMed ID: 30340826
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
14. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
Krishan S; Richardson DR; Sahni S
Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
[TBL] [Abstract][Full Text] [Related]
15. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
Gundelach JH; Madhavan AA; Wettstein PJ; Bram RJ
FASEB J; 2013 Feb; 27(2):782-92. PubMed ID: 23134680
[TBL] [Abstract][Full Text] [Related]
16. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
[TBL] [Abstract][Full Text] [Related]
17. Trypanotoxic activity of thiosemicarbazone iron chelators.
Ellis S; Sexton DW; Steverding D
Exp Parasitol; 2015 Mar; 150():7-12. PubMed ID: 25595343
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
[TBL] [Abstract][Full Text] [Related]
20. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
